I mentioned Nupathe a week or two ago, because I thought Kallender was leaving Insmed to focus on turning around his other baby. Well, well, well... It's up from 1.70 to 2.30 since then, and it's my opinion that this new drug treatment approach to treating migraines is a solid business opportunity. And, they've already received approval from the FDA, so with zero cost burden on those getting the prescription, I "bet" sales will be through the roof! I don't own any shares, though, because I'm all-in with Insmed and don't plan to make a change anytime soon.